CFU -GM assay is used to predict myelosuppression of cells caused by chemical induction as well as to find the haematotoxic potential of chemical compounds and the harmful effects of xenobiotics on the proliferative ability of the progenitors. CFU–GM was assessed on different concentrations (4×10-8 mg/ml to 4×10-1 mg/ml) of potassium nitrate in the bone marrow taken from Charles Foster (CF) rats under inverted microscope at 25X magnification. No such effect of the potassium nitrate was seen which could be related to the molecular mechanism of toxic effect of potassium nitrate used in the study.
CFU-GM assay, Potassium nitrate, Charles Foster rats
Haematotoxicity can be caused by xenobiotics by interfering with committed progenitors, mature blood cells or stem cells following a cytotoxic insult, which make the haematopoietic system to be the limiting factor. In vitro assays are used as screens, as investigative tools, and in the clinical setting of bone marrow transplantation. The screening of drugs leading for low haematotoxicant potentiality is one of the main applications. The in vitro CFU-GM assay is used to predict the haematotoxic potential of chemical compounds, such as myelosuppression of cells, direct harmful effects and the exposure level of xenobiotics on the proliferative ability of the progenitors (1,2). It is also used to study the synergistic and antagonistic effects of many compounds (3). Bone marrow failure can be described by myelotoxicity as a result of adverse effect of xenobiotics on haematopoiesis. Three types of haematopoietic progenitor clonogenic assays: CFU GM assay, BFU-E assay and CFU-MK assay can be used to detect myelotoxicity induced by chemicals, drugs, food and environmental contaminants (4), which can be estimated from the number of surviving progenitors as a function of exposure level on administration of maximum concentration of cytokines (5). Pessina and Bonomi had developed the standard method of CFU-GM assay for evaluation of myelotoxicity of drug (6,7) which is certified by the ECVAM Scientific Advisory Committee (ESAC) for knowing the acute neutropenia in humans as a substitute to using a second species (8,9,10). The assay has many uses in development of antineoplastics and therapy measurments. The frozen cryopreserved bone marrow cells of rat were refined and improved for prediction of haematotoxicity (11) and its variability was evaluated in an international study3 . The use of this technique was reported by Gribaldo and his colleagues (1). The assay provides a lot of information about number of colonies, its potential sensitivity and linearity (January 1997-July 1998). The assays are used to choose the most appropriate animal species for use in preclinical evaluation of compound and therapeutic index-based screening to identify less-myelosupressive analogues for deriving structure-toxicity relationship. As investigative tools they are used for studying mechanisms of haematotoxicity of radiation, chemicals and biological agents. For clinical trials these are used to identify the dependency of myelotoxic effects which provides information about mechanisms of action, plan of cytokine support and estimate dose escalation effect (12). The present study was conducted to check the in vitro haematotoxicity of different concentrations of potassium nitrate on the rat bone marrow cells.
Materials and Method
A number of chemicals were required to conduct the experiment which was purchased from different companies. Iscove’s Modified Dulbeccco Media (IMDM), Bovine Serum Albumin (BSA), Trypan blue and Penicillin-Streptomycin solution were purchased from Sigma-Aldrich Chemical Private Ltd., New Delhi while methyl cellulose , L-glutamine and colony stimulating factor (GM-CSF) were purchased from Bio Basic Inc., India.
Preparation of Methyl Cellulose Culture Media:
For murine bone marrow cells methyl cellulose culture media type A was prepared. It contained 1% methylcellulose in IMDM, 30% FBS, 1% BSA, 2Mm L–glutamine and 10ng/ml granulocyte-macrophage colony stimulating factor (GM-CSF). The bottle containing MCM was thawed overnight at 40C and homogenized by inverting the bottle several times and aliquots were prepared in sterilized tubes.
Preparation of Drug
Potassium nitrate was provided by Merck Specialities Pvt. Ltd., India. The dry powder was reconstituted with autoclaved distilled water and diluted to a concentrated stock solution. The different concentrations of drug dilutions (4×10-8 mg/ml to 4×10-1 mg/ml) were freshly prepared from the stock prior to experiment to avoid degradation.
Preparation of Bone Marrow Cells (BMCs)
Fresh bone marrow cells were collected from the femur of young and healthy male Charles Foster rats and suspended in IMDM supplemented with 30% FBS. After evaluating the percentage of cell viability in a haemocytometer under microscope, the cell suspension was adjusted at 1.5×106 viable cells/ml of suspension.
Colony Forming Assay
The experiment was performed according to Pessina et al., 2001(8). Eight MCM tubes were taken for different concentrations of the compound and one for control. IMDM was added to each tube while toxicant dilution was added in their respective tubes. Immediately after that, equal amount of bone marrow cell suspension was added to each tube and moved gently to mix. Then 1ml of cell medium mixture from each tube was transferred into their respective plate and rotated gently to spread the mixture evenly. The cultures were incubated at 370C with 5% C02 under saturated humidity for 7 days.
Scoring of Colonies
Colonies were counted after 7 days of incubation. The CFU-GM colonies were scored by scanning the whole plate by using an inverted microscope under 25X magnification. The aggregates with 50 or more cells were defined as CFU-GM colonies while aggregates with 20-25 cells were defined as clusters and not counted as colonies.
Result and Discussion
No toxicity was observed at molecular level which could be related to the dose of potassium nitrate (Fig 1-9) (However, dose related insignificant inhibitions of CFU-GM colonies were observed: Fig 5-9). The scientific validation of this model was confirmed by the accuracy of pre-analysis and a broad range of SOP testing, which has many applications in assessment of haematotoxicity. CFU-GM assay enables us to find the results of screening phase which can score different colonies like Compact, Diffuse and spread, Multicentric and Burst forming units(13).
In a study conducted in our laboratory; dose levels of 0, 45, 90 and 135 mg/kg of body weight of potassium nitrate was given to Charles Foster rats for assessment of in vivo toxicity which showed no such adverse effect on vital organs (14). In vitro tests minimize the chances of uncertainties of toxicological investigation as a result of exploitation of animals and human and hence give a clearer picture for calculating clinical dosages (10). The CFU-GM assay lack to predict xenobiotics that are non toxic to haematopoiesis and fail to inhibit neutrophil progenitor as it specifically detects myelosupressive agents (15), mentioned earlier. An algorithm is developed which is capable of recognizing and scoring the CFU-GM colonies by data fusion (16). Recently a non-clonogenic fluorometric microculture cytotoxicity assay (FMCA) has been established as an alternative to CFU-GM assay in preclinical haematotoxicity studies (17).
Another similar study was conducted in our laboratory with Charles Foster rats in which chloramphenicol was administered for 14 days toxicity which caused significant haematotoxicity and hepatotoxicity, which was reversed with the use of coconut water (20ml/kg) in 14 days establishing that coconut water has potential for amelioration of chloramphenicol toxicity (18). Dose related reversible bone marrow depression and fatal aplastic anaemia is caused by Chloramphenicol (19). Earlier researchers suggested that bone marrow showed vacuolation, erythroid maturation arrest, hypocellular marrow and erythroid depletion in chloramphenicol treated rats at different dose level (20,21,22). We will soon conduct the in vitro toxicity of chloramphenicol by using CFU-GM assay in our laboratory.
- Gribaldo L. et al, (1996). The use of in vitro systems for Evaluating Haematotoxicity. The report and recommendations of ECVAM workshop 14, ATLA, 24: 211.
- Pessina A. et al, (2000). Method development for a prevalidation study of in vitro CFU-GM assay for predicting myelotoxicity, Progress in the reduction , Refinement and Replacement of Animal Experimentation, Balls M., Van Zeller AM. and Halder ME. Elsevier Science B.V., Amsterdam, The Netherlands, 31: 679.
- Pessina A. et al, (2010). Prevalidation of rat CFUGM assay for in vitro toxicology applications, ATLA, 38: 105.
- Parent-Massin D., Hymery N. and Sibiril Y. (2010). Stem cells in myelotoxicity, Toxicology, 267(1-3): 112.
- Metcalf D. (1984) The basic biology of haemopoiesis. In The Haemopoietic Colony Stimulating Factors. Metcalf Ed., Amsterdam, 1- 26.
- Pessina A. and Bonomi A. (2007). CFU-GM assay for evaluation of drug Myelotoxic Activity, Curr. Prot. Toxicol., 34: 20.2.1.
- Pessina A. and Bonomi A. (2010). Prediction of potential drug myelotoxicity by in vitro assays on haematopoietic progenitors. Methods in Bioengineering: Alternative technologies to animal testing, Tim Maguire and Eric Novik Eds., Artech House Publishers, Boston, London, 115-131.
- ESAC Statement on the application of CFU-GM assay for predicting acute neutropenia in humans, 24thmeeting of ECVAM Scientific Advisory Committee (ESAC), 20-21 March 2006. European Commission –Joint Research Centre, Institute for health and Consumer Protection, European Centre for Validation of Alternative Methods (ECVAM). Available from: http:// Ecvam.jrc.ec.europa.eu/index.htm, under publications/ ESAC statements.
- Pessina A. et al, (2001). Prevalidation of a model for predicting acute neutropenia by colony forming unit granulocye /macrophage (CFU-GM ) assay, Toxicol. in vitro, 15(6): 729.
- Pessina A. et al, (2003). Application of the CFUGM assay to predict acute drug induced neutropenia: an international blind trial to validate a prediction model for the maximum tolerated dose (MTD) of myelosuppressive xenobiotics, Toxicol. Sci.,75: 355.
- Pessina A., Bonomi A., Baglio C., Cavicchini L. and Gribaldo L. (2009). Refinement and optimization of the rat CFU-GM assay to incorporate the use of cryopreserved bonemarrow cells for in vitro toxicology applications, ATLA, 37: 417.
- Parchment RE., Huang M. and Erickson-Miller CL. (1993). Roles for In Vitro Myelotoxicity Tests in Preclinical Drug Development and Clinical Trial Planning, Toxicol. Path., 21(2): 241.
- . ECVAM DB-ALM: INVITTOX protocol,(2011). Colony Forming Unit- Granulocyte/ Macrophage (CFU-GM) Assay, ECVAM, Europe, 1-22.
- Saxena A. et al, (2011).Toxic Assessment of Potassium Nitrate in Charles Foster Rats with Emphasis on Histopathology of Vital Organs, Res. J. Chem. Environ., 15(3): 77.
- . Pessina A. et al, (2002). In vitro Tests for Haematotoxicity: Prediction of Drug-induced Myelosuppression by the CFU-GM assay, ATLA, 30: 75
- Crosta GF., Fumarola L., Malerba I. and Gribaldo L. (2007). Scoring CFU-GM colonies in vitro by data fusion: A first account, Exp. Hematol., 35: 1.
- Haglund C. et al, (2010). The FMCA-GM assays, high throughput non-clonogenic alternatives to CFU-GM in preclinical haematotoxicity testing, Toxicol. Lett., 194: 102.
- Dubey C., Saxena A., Gupta R., Singh P., Bansode FW. and Singh RK. (2011). Assessment of Toxic Effects of Chloramphenicol in Rats and its Amelioration by Coconut water, Res. J. Chem. Environ., 15(4): 81.
- Mc Curdy PR. (1963). Plasma Concentration of Chloramphenicol and Bone Marrow suppression, Blood, 21(3): 363.
- . Turton JA. et al, (2002). Haematotoxicity of thiamphenicol in the BALB/c mouse and Wistar Hanover rat, Food. Chem. Toxicol., 40(12): 1849.
- . Keiser G. (1974). Co-operative study of patients treated with thiamphenicol. Comparative study of patients treated with chloramphenicol and thiamphenicol, Postgrad. Med. J., 50(5): 145.
- Tomoeda M. and Yamamot K.(1981).The hematologic adverse reaction experience with thiamphenicol in Japan, In Najean Y., Tognoni G. and Yunis AA. Editors, Safety Problems Related to Chloramphenicol and Thiamphenicol, Raven Press, New York, 103–110.